Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer

Eur Urol. 2024 Apr;85(4):396. doi: 10.1016/j.eururo.2023.11.014. Epub 2023 Nov 27.

Authors

Alexander Giesen¹, Wout Devlies², Frank Claessens³, Steven Joniau⁴

Affiliations

¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium.
² Department of Urology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Experimental Endocrinology, KU Leuven, Leuven, Belgium.
³ Laboratory of Experimental Endocrinology, KU Leuven, Leuven, Belgium.
⁴ Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: steven.joniau@uzleuven.be.

PMID: 38016839
DOI: 10.1016/j.eururo.2023.11.014

No abstract available

MeSH terms

Abiraterone Acetate / therapeutic use
Androstenes / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Humans
Male
Phthalazines*
Piperazines*
Prednisone / therapeutic use
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

abiraterone
olaparib
Androstenes
Abiraterone Acetate
Prednisone
Phthalazines
Piperazines